Title	Response: paclitaxel arm
Number of Patients Screened	28
Number of Patients Enrolled	28
Number of Patients Evaluable for Toxicity	28
Number of Patients Evaluated for Efficacy	26
Evaluation Method	RECIST 1.0
Response Assessment CR	n = 7 (27%)
Response Assessment PR	n = 19 (73%)
(Median) Duration Assessments OS	61 months
Title	Survival: paclitaxel arm
Number of Patients Screened	28
Number of Patients Enrolled	28
Number of Patients Evaluable for Toxicity	28
Number of Patients Evaluated for Efficacy	26
Response Assessment CR	n = 8 (31%)
Response Assessment PR	n = 18 (69%)
Title	Response: eribulin arm
Number of Patients Screened	26
Number of Patients Enrolled	24
Number of Patients Evaluable for Toxicity	23
Number of Patients Evaluated for Efficacy	21
Evaluation Method	RECIST 1.0
Response Assessment CR	n = 1 (5%)
Response Assessment PR	n = 20 (95%)
(Median) Duration Assessments OS	61 months
Title	Survival: eribulin arm
Number of Patients Screened	28
Number of Patients Enrolled	28
Number of Patients Evaluable for Toxicity	28
Number of Patients Evaluated for Efficacy	26
Response Assessment CR	n = 8 (31%)
Response Assessment PR	n = 18 (69%)
Outcome Notes
The median follow‐up was 5 years. The median EFS was not reached in either arm, but 5‐year event‐free survival for the eribulin‐based regimen and the paclitaxel‐based regimen was 74.0% and 81.8%, respectively. The median OS was 5.9 years for eribulin and was not reached for the paclitaxel arm, and the 5‐year overall survival for the eribulin‐based regimen and the paclitaxel‐based regimen was 84.4% and 100%, respectively.